Sipai Health Technology Co., Ltd.

思派健康科技有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Code: 0314)

SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2024

Reference is made to the annual report of Sipai Health Technology Co., Ltd. (the "**Company**") for the year ended December 31, 2024 published on April 29, 2025 (the "**Annual Report**"). Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meaning as those defined in the Annual Report. In addition to the disclosure made by the Company in the Annual Report, the Company wishes to provide the following information in respect of the share schemes of the Company, namely the 2017 Plan, the RSU Scheme and the 2023 Share Award Scheme.

2017 PLAN

The table below shows the details of the outstanding 2017 Plan Options as at the date of the Annual Report (i.e. March 18, 2025) (the "**Annual Report Date**") and the date of this announcement (the "**Announcement Date**"), respectively:

Grantees	Outstanding as at the Annual Report Date	Approximate percentage of total number of Shares (excluding treasury Shares) in issue as at the Annual Report Date	Outstanding as at the Announcement Date	Approximate percentage of total number of Shares (excluding treasury Shares) in issue as at the Announcement Date
Employee	5,970,317	0.78%	4,883,320	0.65%
Service Provider	804,900	0.11%	733,900	0.10%
Total	**6,775,217**	**0.89%**	**5,617,220**	**0.75%**

Remaining Life of the 2017 Plan

The 2017 Plan commenced in January 2018 and shall continue in effect for a term of ten years. At the end of the Reporting Period, the remaining life of the Share Award Scheme shall be approximately three (3) years.

RSU SCHEME

The table below shows the details of the outstanding RSUs as at the Annual Report Date and the Announcement Date, respectively:

Grantees	Outstanding as at the Annual Report Date	Approximate percentage of total number of Shares (excluding treasury Shares) in issue as at the Annual Report Date	Outstanding as at the Announcement Date	Approximate percentage of total number of Shares (excluding treasury Shares) in issue as at the Announcement Date
ZHOU Teng	Nil	Nil	N/A	N/A

Remaining Life of the RSU Scheme

The RSU Scheme commenced in June 2021 and shall continue in effect for a term of ten years. At the end of the Reporting Period, the remaining life of the Share Award Scheme shall be approximately six (6) years.

On August 18, 2025, by considering that all the underlying Shares under the RSU Scheme have been duly vested pursuant to the RSU Scheme and the trustee did not hold any funds or properties, the Board resolved to early terminate (i) the RSU Scheme, (ii) the trustee appointment, and (iii) the trust arrangement which were set up pursuant to the RSU Scheme previously. For details, please see the interim report of 2025 of the Company published on September 26, 2025.

2023 SHARE AWARD SCHEME

The maximum aggregate number of the shares awarded under the 2023 Scheme was 8% of the issued share capital of the Company as at the Adoption Date (representing approximately 7.99% of the issued share capital of the Company as at the Annual Report Date). As of the Annual Report Date and the Announcement Date, the trustee purchased 42,297,400 Shares and 60,820,600 Shares in aggregate on the market, representing approximately 5.56% and 8.10% of Shares (excluding treasury Shares) in issue (representing approximately 7.97% of Shares in issue as at the Adoption Date), respectively. The Shares so purchased will be used as Awards for the Eligible Participants under the Scheme to incentivize them to make contribution to the Group. As of the Announcement Date, the Company has not yet granted any Shares under the Scheme.

Remaining Life of the 2023 Share Award Scheme

The 2023 Share Award Scheme commenced in August 2023 and shall continue in effect for a term of ten years. At the end of the Reporting Period, the remaining life of the Share Award Scheme shall be approximately eight (8) years.

The above additional information does not affect the other information contained in the Annual Report. Save as disclosed above, all the other information in the Annual Report remain unchanged.

By Order of the Board
Sipai Health Technology Co., Ltd.
MA Xuguang
Chairman of the Board and Executive Director

Hong Kong, October 16, 2025

As at the date of this announcement, the Board comprises Mr. MA Xuguang and Mr. LI Ji as executive directors, Mr. YAO Leiwen as non-executive director, Mr. FAN Xin, Mr. HE Haijian and Ms. HUANG Bei as independent non-executive directors.